Key Summary Points {#FPar1}
==================

**Why carry out this study?**Exenatide once weekly (EQW) has a well-established safety and efficacy profile and is primarily renally eliminated.The safety profile of EQW is well established in people with chronic kidney disease stage 2 (CKD2; mild renal impairment); in the current analysis, we therefore compared this safety profile with data from people with CKD stage 3 (CKD3; moderate renal impairment).We evaluated the efficacy and renal and gastrointestinal tolerability of EQW in patients with type 2 diabetes and CKD (CKD3 vs. CKD2).**What was learned from the study?**Pooled analysis of eight phase 3, 26/28-week, double-blind or open-label studies of EQW showed it to be well-tolerated and with similar efficacy in participants with type 2 diabetes who also had mild or moderate renal impairment.The study provides users and healthcare providers with further knowledge on exenatide's tolerability and efficacy in people with type 2 diabetes and different degrees of renal impairment.

Introduction {#Sec1}
============

Type 2 diabetes is the most common cause of chronic kidney disease (CKD) in developed countries \[[@CR1]\]. Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used for the treatment of hyperglycaemia in people with type 2 diabetes \[[@CR2]\]. The safety and efficacy of exenatide once weekly (EQW) administered as a subcutaneous injection are well established in the general population with type 2 diabetes \[[@CR2]\]. Exenatide has not been shown to have any direct nephrotoxic effects \[[@CR3], [@CR4]\], but it is predominantly metabolised by proteolytic degradation after renal filtration \[[@CR5]\]. A reduced clearance could therefore lead to an increased frequency of gastrointestinal adverse events (AEs) in people with severe renal impairment, potentially leading to dehydration and an increased risk for acute kidney injury.

People with mild or moderate renal impairment, compared with those with normal renal function, have also been reported to have an increase in EQW exposure \[[@CR3], [@CR5]\] (although not to a clinically relevant degree). As exenatide is the first once-weekly GLP-1 RA to be commercially available, there has been a strong focus on its gastrointestinal and renal AE profile. Because regulatory authorities have been inconsistent when considering the suitability of EQW in people with CKD \[[@CR3], [@CR5], [@CR6]\], there is a strong rationale to re-evaluate EQW's risk--benefit profile in people with type 2 diabetes who have CKD at different stages. Such a re-evaluation is especially relevant given that data from the EXSCEL (Exenatide Study of Cardiovascular Event Lowering) trial, which included participants with an estimated glomerular filtration rate (eGFR) as low as 30 mL/min/1.73 m^2^, suggest a possible positive effect of EQW on CKD progression (i.e. significant reduction in an adjusted composite outcome of 40% eGFR decline, new macroalbuminuria, renal replacement therapy or renal death) \[[@CR7]\]. It is also important to compare the tolerability of EQW with that of other anti-hyperglycaemic drugs in renally impaired people with type 2 diabetes.

Because the safety profile of EQW is well established in people with CKD stage 2 (CKD2; mild renal impairment; eGFR ≥ 60 to \< 90 mL/min/1.73 m^2^) \[[@CR8]\], in the analysis reported here we compared this profile using data from people with CKD stage 3 (CKD3; moderate renal impairment; eGFR ≥ 30 to \< 60 mL/min/1.73 m^2^) who received treatment with EQW or a placebo/non--GLP-1 RA comparator. The objective of this study was, therefore, to summarise the efficacy and tolerability of EQW in terms of renal and gastrointestinal AEs in people with type 2 diabetes with CKD3 or CKD2.

Methods {#Sec2}
=======

Study Design and Participant Populations {#Sec3}
----------------------------------------

This post hoc analysis evaluated the pooled safety and efficacy data from eight previously published double-blind or open-label studies \[[@CR9]--[@CR16]\] (see Electronic Supplementary Material \[ESM\] Table S1). The studies included participants with mild or moderate baseline CKD who were treated with EQW, placebo or sitagliptin, metformin, pioglitazone, dapagliflozin or insulin.

The rationale for selecting these eight studies for pooling was based on the following criteria: (1) all studies (four open-label, four double-blind) were phase 3 safety and efficacy studies with a controlled treatment period of 26--28 weeks (to reflect an adequate treatment period for assessment; results were combined for the week 26/28 endpoint); (2) all studies included a treatment group with EQW in either of the two currently available formulations (aqueous formulation or non-aqueous suspension, both 2 mg, administered subcutaneously once weekly); (3) all studies included a comparator group(s) (active or placebo) other than another GLP-1 RA (studies with only another GLP-1 RA as a comparator were excluded to provide an objective view of EQW's GLP-1-related effect in relation to renal function).

Only the controlled treatment periods were analysed because in some studies participants taking comparators were switched to EQW for the extension period and the lengths of the extension periods varied between studies.

Participants were pooled across the eight studies and classified into two treatment groups: (1) EQW and (2) all comparators. Participants were also classified into two subgroups based on the baseline eGFR value, namely CKD3 and CKD2, with eGFR estimated using the 4-variable Modification of Diet in Renal Disease (MDRD-4) formula \[[@CR17]\] or the 3-variable Japanese equation \[[@CR18]\] (for study GWBX \[[@CR15]\] conducted in Japan), to provide more reliable eGFR calculations in Japanese participants.

All studies complied with the Helsinki Declaration of 1964 and its later amendments, and other relevant ethical guidelines, and all participants had provided written informed consent. Each study site involved in the eight studies received approval of their respective local ethics committees.

Outcome Measures {#Sec4}
----------------

### Efficacy {#Sec5}

Efficacy was evaluated by the absolute change from baseline to the end of the 26-/28-week controlled period for glycated haemoglobin (HbA~1c~), body weight and sitting systolic blood pressure (SBP).

### Safety {#Sec6}

The proportions of participants with AEs, AEs leading to discontinuation of treatment, serious AEs and AEs of special interest (AESIs; i.e. acute renal failure and dehydration-related events, hypoglycaemia and gastrointestinal events) during the 26/28-week controlled treatment period were calculated and presented by treatment group and CKD subgroup. The Medical Dictionary for Regulatory Activities (MedDRA) version 21.1 (<https://www.meddra.org/>) was used for AE coding. AEs were recorded throughout the studies, and AESIs were evaluated by summarising AEs using Standardised MedDRA Queries (SMQs; for dehydration and acute renal failure) or by system organ class and preferred terms (for gastrointestinal AEs). Events of major hypoglycaemia were defined according to each study's criteria; further details can be found in the ESM.

The crude AE incidence rate was calculated as the total number of participants in a pooled treatment group with an AE divided by the total number of participants in that pooled treatment group. Study size-adjusted rates (based on giving each study a weight) were also calculated to account for imbalances in randomisation ratios in two of the studies \[[@CR13], [@CR16]\]. However, only the crude rates are presented because they were similar to the study size-adjusted rates.

Heart rate and laboratory results, including eGFR and urinary albumin-to-creatinine ratio, are presented as baseline and week 26/28 change from baseline results.

Statistical Analyses {#Sec7}
--------------------

Two participant populations were defined for these analyses: (1) the safety analysis set, which was defined as all participants who were randomised and took at least one dose of the study medication; participants were analysed as treated rather than as randomised (used for safety results); and (2) the intention-to-treat (ITT) analysis set, which was defined as all randomised participants who received at least one dose of study medication and had at least one post-baseline HbA~1c~ assessment; participants were analysed as randomised rather than as treated (used for participant demographics/baseline characteristics and efficacy results).

HbA~1c~, body weight, SBP and eGFR results at baseline and week 26/28 and change in results from baseline to week 26/28 were summarised descriptively (mean, standard deviation); an analysis of covariance model that included treatment group and study as fixed effects and the continuous baseline value of the variable as a covariate was also used to analyse the change-from-baseline results. Point estimates (least squares mean estimates, standard errors) and corresponding two-sided 95% confidence intervals (CIs) for absolute change from baseline to week 26/28 were derived. Baseline was defined as the latest non-missing assessment prior to the first dose of randomised study medication. For the analysis of post-baseline results, only those results collected during the week 26/28 controlled period were included in the analysis (i.e. an all-completers analysis). No imputation was conducted for missing week 26/28 results.

Three studies (DURATION-7, DURATION-8 and BCB120) \[[@CR12]--[@CR14]\] offered participants rescue medication (prandial insulin, basal insulin and glucose-lowering therapy, respectively). Efficacy results after rescue medication use in these studies were excluded for the HbA~1c~ and body weight analyses but not for the SBP and eGFR analyses because the rescue medication theoretically should not affect these measurements. The other five studies did not specifically offer rescue medications to the participants. All results after treatment discontinuation were excluded.

All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results {#Sec8}
=======

Participant Demographics and Baseline Characteristics {#Sec9}
-----------------------------------------------------

Participants with CKD3 (*N* = 182) or CKD2 (*N* = 772) at baseline receiving EQW differed in a number of baseline characteristics, including age \< 65 years (56% vs. 79%, respectively), mean body mass index (28.3 vs. 31.6 kg/m^2^, respectively) and mean duration of type 2 diabetes (9.7 vs. 7.6 years, respectively), whereas mean blood pressure (133/77 vs. 131/79 mmHg, respectively) and mean HbA~1c~ (8.3% vs. 8.5%, respectively) were similar (Table [1](#Tab1){ref-type="table"}). The safety analysis set produced similar values to the ITT analysis set (data not shown).Table 1Demographics and baseline characteristics for participants with type 2 diabetes by baseline chronic kidney disease category---8-study pool (intention-to-treat analysis set)CharacteristicCKD3CKD2EQW (*N* = 182)All comparators (*N* = 207)EQW (*N* = 772)All comparators (*N* = 1043)Men, *n* (%)105 (57.7)105 (50.7)419 (54.3)608 (58.3)Age (years) Mean (SD)62.5 (9.0)62.2 (9.0)56.9 (9.3)56.9 (9.5) \< 65, *n* (%)102 (56.0)120 (58.0)613 (79.4)820 (78.6)Race, *n* (%) White66 (36.3)89 (43.0)522 (67.6)685 (65.7) Asian111 (61.0)106 (51.2)157 (20.3)227 (21.8) Black or African American05 (2.4)38 (4.9)39 (3.7)Body weight (kg), mean (SD)76.9 (19.3)78.5 (17.7)88.8 (19.3)^a^87.8 (19.1)BMI (kg/m^2^), mean (SD)28.3 (5.1)29.6 (5.8)31.6 (5.5)^a^31.4 (5.6)BMI ≥ 35 (kg/m^2^), *n* (%)24 (13.2)40 (19.3)196 (25.4)246 (23.6)Sitting SBP (mm Hg), mean (SD)133 (14.3)136 (17.2)131 (13.8)131 (14.6)Sitting DBP (mm Hg), mean (SD)77 (9.7)79 (9.6)79 (9.3)79 (8.8)eGFR (mL/min/1.73 m^2^), mean (SD)52.7 (5.6)53.3 (5.1)75.9 (8.4)75.9 (8.6)uACR (mg/g), mean (SD), median105 (348),14.2*n* = 151116 (438),20.4*n* = 16554.1 (171),10.6*n* = 52847.9 (158),10.6*n* = 810 \< 30 mg/g (normal), *n* (%)96 (52.7)108 (52.2)398 (51.6)609 (58.4) ≥ 30 to ≤ 300 mg/g (moderately increased albuminuria), *n* (%)45 (24.7)46 (22.2)108 (14.0)178 (17.1) \> 300 mg/g (severely increased albuminuria), *n* (%)10 (5.5)11 (5.3)22 (2.8)23 (2.2) Unknown^b^, *n* (%)31 (17.0)42 (20.3)244 (31.6)233 (22.3)Duration of T2D (years), mean (SD)9.7 (6.8)9.5 (6.8)7.6 (6.3)^a^6.3 (5.5)^a^HbA~1c~ (%), mean (SD)8.3 (0.8)8.5 (0.9)8.5 (1.1)8.4 (1.1)FPG (mg/dL), mean (SD)168 (46.7)*n* = 181176 (50.2)*n* = 203172 (50.0)*n* = 751171 (46.8)*n* = 1026Baseline anti-hyperglycaemic drugs, *n* (%)^c^ None8 (4.4)34 (16.4)135 (17.5)299 (28.7) Metformin155 (85.2)159 (72.5)529 (68.5)647 (62.0) Sulfonylureas4 (2.2)10 (4.8)55 (7.1)55 (5.3) Thiazolidinediones36 (19.8)31 (15.0)32 (4.1)39 (3.7) Insulin18 (9.9)22 (10.6)107 (13.9)98 (9.4)*BMI* Body mass index, *CKD* chronic kidney disease, *CKD2* stage 2 CKD, *CKD3* stage 3 CKD, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *EQW* exenatide once weekly, *FPG* fasting plasma glucose, *HbA*~*1c*~ glycated haemoglobin, *N* number of participants in the pooled treatment group, *n* number of participants in analysis, *SBP* systolic blood pressure, *SD* standard deviation, *T2D* type 2 diabetes, *uACR* urinary albumin-to-creatinine ratio^a^One participant had no result^b^uACR was not determined in two studies (DURATION-7 and DURATION-8)^c^One additional participant took repaglinide (EQW, CKD2), which was not a permitted background anti-hyperglycaemic drug per the protocol

Participants with CKD3 receiving EQW were mostly Asian (61% vs. 20% with CKD2) as 59% were from a study conducted in Japan \[[@CR15]\].

Median treatment duration was similar between participants receiving EQW with CKD3 (183 days) and CKD2 (189 days).

Efficacy {#Sec10}
--------

Mean changes from baseline to week 26/28 in HbA~1c~, body weight and SBP were similar between the CKD3 and CKD2 subgroups for participants receiving EQW. Both CKD subgroups of participants receiving EQW had clinically meaningful adjusted mean reductions in HbA~1c~. Adjusted mean reductions were also observed for body weight and SBP, independent of the stage of renal impairment (Fig. [1](#Fig1){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}).Fig. 1Analysis of covariance-adjusted mean change in HbA~1c~, body weight and SBP from baseline to week 26/28 for participants with type 2 diabetes treated with EQW, by baseline CKD category (8-study pool \[intention-to-treat analysis set\]). *CKD* chronic kidney disease, *CKD2* stage 2 CKD, *CKD3* stage 3 CKD, *EQW* exenatide once weekly, *HbA*~*1c*~ glycated haemoglobin, *LS* least squares, *N* number of participants in the pooled treatment group, *n* number of participants with observed baseline and week 26 or 28 values, *SBP* systolic blood pressure. Change from baseline to week 26/28 = (week 26/28 post-baseline value − baseline value)Table 2Analysis of covariance-adjusted mean change in glycated haemoglobin, body weight and systolic blood pressure from baseline to week 26/28 for participants with type 2 diabetes treated with exenatide once weekly, by baseline chronic kidney disease category---8-study pool (intention-to-treat analysis set)StatisticHbA~1c~ (%)Body weight (kg)SBP (mmHg)CKD3 (*N* = 182)CKD2 (*N* = 772)CKD3 (*N* = 182)CKD2 (*N* = 772)CKD3 (*N* = 182)CKD2 (*N* = 772)*n*150591150607150613Baseline mean (SD)^a^8.32 (0.83)8.52 (1.06)76.4 (19.7)88.2 (19.4)132.7 (13.8)131.0 (13.9)Week 26/28 mean (SD)7.10 (0.93)7.15 (1.12)73.7 (19.2)86.0 (19.1)127.7 (13.9)129.0 (14.5)Adjusted change from baseline to week 26/28, LS mean (SE)^b^− 1.46 (0.15)− 1.37 (0.04)− 2.61 (0.54)− 2.18 (0.16)− 2.0 (2.07)− 2.2 (0.52)95% two-sided CI− 1.75, − 1.17− 1.45, − 1.28− 3.68, − 1.55− 2.49, − 1.87− 6.1, 2.1− 3.2, − 1.2Analysis excludes measurements taken after rescue therapy (only HbA~1c~ and body weight for three studies \[[@CR12]--[@CR14]\]) and after premature treatment discontinuation*CI* Confidence interval, *CKD* chronic kidney disease, *CKD2*stage 2 CKD, *CKD3* stage 3 CKD, *HbA*~*1c*~ glycated haemoglobin, *LS* least squares, *N* number of participants in the pooled treatment group, *n* number of participants with observed baseline and week 26 or 28 values, *SD*standard deviation, *SE* standard error^a^Baseline is defined as the last non-missing assessment before the first dose of randomised study medication^b^Change from baseline to week 26/28 post-baseline was calculated as: (week 26/28 post-baseline value − baseline value). Adjusted (LS) means in change from baseline values at week 26/28 are modelled using analysis of covariance (ANCOVA), including study and treatment group as fixed effects and baseline value as a covariate

Safety {#Sec11}
------

As shown in Table [3](#Tab3){ref-type="table"}, a higher proportion of participants were reported as having any AE in the CKD3 subgroup (81% \[EQW\] and 74% \[all comparators\]) than in the CKD2 subgroup (72% \[EQW\] and 68% \[all comparators\]), irrespective of the treatment.Table 3Safety parameters and adverse events of special interest for participants with type 2 diabetes, by baseline chronic kidney disease category---8-study pool (safety analysis set)Parameter or SMQ/preferred term^a^AE incidence rate,*n* (%) of participantsCKD3CKD2EQW (*N* = 187)All comparators (*N* = 210)EQW (*N* = 784)All comparators (*N* = 1063)Any AE151 (80.7)155 (73.8)567 (72.3)727 (68.4)Any AE leading to discontinuation of treatment^b^15 (8.0)8 (3.8)39 (5.0)23 (2.2)Any AE with outcome of death1 (0.5)01 (0.1)3 (0.3)Any SAE5 (2.7)13 (6.2)27 (3.4)52 (4.9) Acute kidney injury1 (0.5)001 (0.1)Any SAE leading to discontinuation of treatment3 (1.6)4 (1.9)7 (0.9)6 (0.6)AESI Gastrointestinal disorders (SOC)^c^79 (42.2)39 (18.6)257 (32.8)200 (18.8)  Nausea30 (16.0)7 (3.3)122 (15.6)52 (4.9)  Diarrhoea22 (11.8)12 (5.7)72 (9.2)58 (5.5)  Constipation17 (9.1)5 (2.4)48 (6.1)28 (2.6)  Vomiting14 (7.5)6 (2.9)48 (6.1)24 (2.3)  Abdominal discomfort11 (5.9)3 (1.4)7 (0.9)3 (0.3)  Dyspepsia7 (3.7)1 (0.5)21 (2.7)21 (2.0)  GORD5 (2.7)2 (1.0)13 (1.7)6 (0.6)  Flatulence4 (2.1)1 (0.5)11 (1.4)5 (0.5)  Eructation4 (2.1)07 (0.9)0  Abdominal pain3 (1.6)2 (1.0)16 (2.0)13 (1.2)  Abdominal distension1 (0.5)1 (0.5)16 (2.0)7 (0.7) Dehydration (SMQ narrow) AEs^d^0000 Acute renal failure (SMQ narrow) AEs^e^1 (0.5)01 (0.1)3 (0.3)  Acute kidney injury1 (0.5)001 (0.1)  Renal failure001 (0.1)2 (0.2) Any hypoglycaemia19 (10.2)49 (23.3)109 (13.9)157 (14.8)  Major hypoglycaemia1 (0.5)001 (0.1)  Minor hypoglycaemia3 (1.6)14 (6.7)37 (4.7)50 (4.7)  Other17 (9.1)45 (21.4)93 (11.9)130 (12.2)AEs are presented as *n* (%) of participants; 26- or 28-week treatment period AEs occur on or after first randomised study drug dose day through to end of controlled treatment period. Participants with multiple events are counted once per category but can be counted in more than one category*AE* Adverse event, *AESI* AE of special interest, *CKD* chronic kidney disease, *CKD2* stage 2 CKD, *CKD3* stage 3 CKD, *EQW* exenatide once weekly, *GORD* gastro-oesophageal reflux disease, *MedDRA* Medical Dictionary for Regulatory Activities, *N* number of participants in the pooled treatment group, *n* number of participants in analysis, *SAE* serious AE, *SMQ* Standardised MedDRA Query, *SOC* system organ class^a^MedDRA version 21.1 (<https://www.meddra.org/>) was used for AE coding^b^AEs leading to discontinuation from study (all eight studies) and AEs leading to discontinuation of study treatment (D5553C00003, D5553C00002) \[[@CR12], [@CR14]\]^c^Only preferred terms with rates  ≥ 2.0% in any subgroup are shown^d^Includes six preferred terms in SMQ search; only those with any incidence are shown^e^Includes 18 preferred terms in SMQ search; only those with any incidence are shown

The frequencies and types of serious AEs (SAEs) were low and similar across treatment groups and between the CKD3 and CKD2 subgroups (CKD3: EQW 3% and all comparators 6% of participants; CKD2: EQW 3% and all comparators 5% of participants).

AEs leading to discontinuation of study treatment were reported for 8% of participants in the EQW group and 4% of participants in the all comparators group in the CKD3 subgroup, and for 5% and 2%, respectively, in the CKD2 subgroup.

A larger proportion of participants receiving EQW with CKD3 than those with CKD2 were reported to experience gastrointestinal disorders (42.2% \[CKD3\] and 32.8% \[CKD2\] for EQW; 18.6% \[CKD3\] and 18.8% \[CKD2\] for all comparators); however, similar proportions were reported to experience nausea (16.0% \[CKD3\] and 15.6% \[CKD2\] for EQW; 3.3% \[CKD3\] and 4.9% \[CKD2\] for all comparators) and vomiting (7.5% \[CKD3\] and 6.1% \[CKD2\] for EQW; 2.9% \[CKD3\] and 2.3% \[CKD2\] for all comparators). The term related to gastrointestinal disorders with the largest variation between the two CKD subgroups was abdominal discomfort, which was recorded in 5.9% (CKD3) and 0.9% (CKD2) of the participants receiving EQW.

There were no cases of dehydration in any group.

Overall, five participants experienced any AE potentially related to acute renal failure; however, only two participants had an SAE of acute kidney injury.

EQW treatment was also not associated with an increase in hypoglycaemic events in participants in the CKD3 subgroup compared with the CKD2 subgroup.

Renal function, as evaluated by eGFR, changed over time on average, with a similar magnitude in the EQW group as in the all comparators group in both CKD subgroups. The difference in adjusted mean change from baseline to week 26/28 between the EQW and the all comparators group was 0.8 mL/min/1.73 m^2^ (95% CI − 2.4, 4.0) for the CKD3 subgroup and − 0.9 mL/min/1.73 m^2^ (95% CI − 2.4, 0.6) for the CKD2 subgroup.

The proportion of participants experiencing a post-baseline increase in serum creatinine ≥ 1.5-fold the baseline value was low and similar in participants receiving EQW in the CKD3 and CKD2 subgroups (Table [4](#Tab4){ref-type="table"}). Median change from baseline to week 26/28 in the urinary albumin-to-creatinine ratio for participants receiving EQW was − 3.5 mg/g in the CKD3 subgroup and − 2.7 mg/g in the CKD2 subgroup. Overall, treatment with EQW did not result in worsening of the renal function in either CKD subgroup.Table 4Descriptive results of changes in laboratory and clinical parameters from baseline to week 26/28 for participants with type 2 diabetes, by baseline chronic kidney disease category---8-study pool (safety analysis set)ParameterCKD3CKD2EQW (*N* = 187)All comparators (*N* = 210)EQW (*N* = 784)All comparators (*N* = 1063)eGFR (mL/min/1.73 m^2^) at baseline, mean (SD)^a^52.6 (5.6)53.3 (5.1)75.9 (8.4)76.0 (8.6) Change from baseline, mean (SD)9.3 (13.9)*n* = 1477.9 (14.8)*n* = 1672.5 (16.0)*n* = 5753.4 (13.7)*n* = 769Serum creatinine ≥ 1.5-fold baseline value, *n* (%)^b^2 (1.1)1 (0.5)11 (1.4)7 (0.7)uACR (mg/g) at baseline, median (minimum, maximum)14.2(0.9, 2938.0)*n* = 15620.4(0.9, 4211.7)*n* = 16710.6(0.9, 1991.1)*n* = 53810.6(0.9, 2178.0)*n* = 825 Change from baseline (mg/g), median (minimum, maximum)− 3.5(− 1315.3, 9893.7)*n* = 119− 2.7(− 1098.3, 736.9)*n* = 134− 2.7(− 744.0, 534.1)*n* = 364− 0.9(− 1105.4, 1004.4)*n* = 565Heart rate (bpm) at baseline, mean (SD)74.7 (11.6)73.9 (10.9)74.4 (9.8)73.7 (10.1) Change from baseline (bpm), mean (SD)4.2 (10.7)*n* = 1500.6 (7.7)*n* = 1732.7 (10.0)*n* = 614− 0.3 (9.5)*n* = 818*bpm* Beats per minute, *CKD* chronic kidney disease, *CKD2* stage 2 CKD, *CKD3* stage 3 CKD, *eGFR*estimated glomerular filtration rate, *EQW* exenatide once weekly, *N* number of participants in the pooled treatment group, *n* number of participants in analysis, *SD* standard deviation, *uACR* urinary albumin-to-creatinine ratio^a^eGFR for all studies was calculated on the basis of the 4-variable Modification of Diet in Renal Disease equation: 175 × serum creatinine (mg/dL)^−1.154^ × Age (years)^−0.203^ × 1.212 (black) × 0.742 (women) except for study H8O-JE-GWBX \[[@CR15]\], which used the 3-variable Japanese equation: 194 × serum creatinine (mg/dL)^−1.094^ × Age (years)^−0.287^  × 0.739 (women)^b^Serum creatinine value ≥ 1.5-fold the baseline value at any time during the 26/28-week controlled treatment period

For EQW participants, small mean increases in heart rate were observed in both CKD subgroups (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec12}
==========

This analysis of the pooled results of eight studies reporting on treatment with EQW over approximately 6 months showed EQW to be well tolerated in participants with type 2 diabetes and mild, as well as moderate, renal disease. Further, the mean results showed EQW to have clinically meaningful improvements in HbA~1c~ in both participants with CKD3 and CKD2, i.e. irrespective of renal function in patients with an eGFR ≥ 30 mL/min/1.73 m^2^.

Approximately one fifth of people with type 2 diabetes have comorbid CKD (defined as stages 3--5 or dialysis) \[[@CR19]\], with up to one third of these developing CKD over a 4-year period \[[@CR20]\]. These data underscore the importance of treatment options that can be safely and effectively used in this population. Previous studies have found that in mild or moderate renal impairment, no dosage adjustments of exenatide are needed \[[@CR21]\], although reduced renal clearance leading to poor gastrointestinal tolerability limits its use in severe renal impairment (creatinine clearance \< 30 mL/min) or end-stage renal disease \[[@CR21]\]. Other GLP-1 RAs, such as albiglutide, dulaglutide and liraglutide, are not dependent on renal clearance for their degradation \[[@CR22]\]. However, care still needs to be taken regarding their gastrointestinal tolerability profiles and the risk for dehydration and potential subsequent acute kidney injury.

The safety and efficacy results of this pooled analysis are consistent with those of the individual studies included herein \[[@CR9]--[@CR16]\] and with other pooled analyses of EQW \[[@CR23], [@CR24]\]. Although EQW was generally well tolerated in participants with CKD3, the proportion of participants who discontinued due to an AE was slightly higher for participants with CKD3 (8%) than for those with CKD2 (5%), largely attributable to gastrointestinal disorders, and possibly because this is a population with more comorbidities. These rates were also respectively higher than those in participants with CKD3 (4%) and CKD2 (2%) receiving comparator drugs. A higher proportion of participants were reported to have any AE in the CKD3 than in the CKD2 subgroup, irrespective of treatment group. Overall, the rates of any gastrointestinal disorder by system organ class were higher in participants receiving EQW than in those receiving comparator drugs or placebo. Moreover, the rates were higher in participants receiving EQW in the CKD3 subgroup compared with the CKD2 subgroup. However, the proportion of participants receiving EQW who experienced nausea was similar in the CKD3 and CKD2 subgroups (approx. 16%), as was that of vomiting (approx. 6--8%). The events most responsible for the difference in gastrointestinal tolerability between the EQW CKD subgroups were related to abdominal discomfort and constipation. Analyses evaluating the time-course of gastrointestinal AEs associated with EQW treatment indicate that the rate of these events diminishes over time \[[@CR23], [@CR25]\] and that no dose titration is needed upon treatment introduction due to the slow release of active drug from the extended-release formulation.

Frequencies for nausea and vomiting for GLP-1 RAs that are not dependent on renal filtration for their clearance have also been examined in people with CKD. In the LIRA-RENAL study \[[@CR26]\], which examined the efficacy and safety of liraglutide 1.8 mg/day, and the PIONEER 5 \[[@CR27]\], which looked at the efficacy and safety of oral semaglutide up to 14 mg/day, participants with uncontrolled type 2 diabetes and CKD3 treated for 26 weeks experienced nausea (21.4% and 19%, respectively) and vomiting (12.1% and 12%, respectively). In the AWARD-7 study, dulaglutide was examined in a 52-week trial in participants with moderate to severe CKD. Participants receiving the lower dulaglutide dose of 0.75-mg once weekly experienced nausea (14%) and vomiting (8%), with substantially higher incidences reported with the 1.5-mg/once-weekly dose \[[@CR28]\].

The current analysis has several strengths, such as inclusion of several individual studies that randomised collectively a wide variety of people with type 2 diabetes. Moreover, this analysis has a strong representation of Asian participants, a population that is often underrepresented in existing GLP-1 RA studies. The analysis thus provides data in this group of individuals who, because of pathophysiological differences (such as type 2 diabetes that is primarily characterised by beta-cell dysfunction as opposed to insulin resistance \[[@CR29]\]) and generally a lower body weight, may respond differently to GLP-1 RAs. However, the large proportion of Japanese participants in our analysis could also be considered a limitation as study heterogeneity could potentially skew the results. Other limitations include the fact that the study duration was only approximately 6 months, thus diminishing the possibility of detecting rare AEs or AEs that could develop or be detected over a longer time. By contrast, the 6-month period should have been long enough to fully describe any differences in gastrointestinal tolerability or volume depletion due to differences in renal function and drug clearance. In addition, the current pooled analysis gives a valuable opportunity for a more detailed study of the gastrointestinal AE profile in people with renal impairment, whereas the large-scale cardiovascular outcome trial, EXSCEL, gave a clear indication of long-term cardiovascular safety also in the pre-defined subgroup of participants receiving EQW with eGFR below 60 mL/min/1.73 m^2^ \[[@CR8]\].

Conclusions {#Sec13}
===========

The pooled results of eight studies show that EQW treatment in participants with type 2 diabetes with CKD3 (moderate renal impairment), as well as in those with CKD2 (mild renal impairment), is well tolerated, with results consistent with EQW's established safety profile. Efficacy improvements, including changes in HbA~1c~, body weight and SBP, were consistent with the known treatment effects of the drug and were generally similar between participants with CKD3 and CKD2.
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